Zephyr AI – a healthcare technology company focused on developing artificial intelligence (AI) solutions for democratizing precision medicine – announced it has closed a $111 million Series A funding round with participation from Revolution Growth, Eli Lilly & Company, Jeff Skoll, EPIQ Capital Group, and others.
The company has developed improved data federation tools with various machine-learning algorithms in oncology and cardiometabolic diseases.
The funding will enable Zephyr AI to enhance its analytical speed and fortify its extensive training and validation data set collection. It will also support expanding the company’s scientific and commercial teams to expedite the delivery of the rapidly growing pipeline of insights to the market.
Cooley LLP served as the legal counsel for Zephyr AI.
KEY QUOTES:
“The US has the highest rate of avoidable cancer and cardiometabolic-related deaths among any high-income country. We must do better. At Zephyr AI, we are harnessing the power of AI to extract novel insights to better define patient stratification and response predictions as well as improve federation of real-world data. With our world-class team, and the support of this investor group, we are deploying one of the largest clinicogenomic datasets that has unprecedented breadth across disease states and data partners. Collectively, we are now well positioned to support our mission of democratizing precision medicine, enhancing both the speed and success of clinical trials.”
- Grant Verstandig, Zephyr AI’s Co-Founder and Executive Chairman
“First, it has empirically demonstrated the ability to navigate the intricacies of real-world patient data, historically a challenge in the field. Second, leveraging recent breakthroughs in representation learning, the technology elucidates the biological context underlying its predictions. This contextual understanding is pivotal in drug development decision-making, revealing patient selection insights unpredictable using today’s tools to maximize the value of both approved medicines and drugs in development.”
- Dr. Justin Stebbing, Chairman of Zephyr AI’s Scientific and Medical Advisory Board, Editor of Oncogene and Professor of Biomedical Sciences at ARU, Cambridge – who noted that the company’s tech stands out in two dimensions
“The expansion of our diverse multimodal data resources will accelerate the advancement of Zephyr AI’s algorithms, paving the way for us to transform the landscape of precision medicine and improve outcomes for our partners and patients.”
“We are excited to be part of this growing ecosystem of AI-enabled drug development and welcome the opportunity to attend AACR where we will engage with the scientific community and present some of our emerging scientific insights from our platform.”
- Jeff Sherman, Co-Founder, Interim CEO, and Chief Technology Officer of Zephyr AI
